Clinical trial NCT03686657: Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients
Official title: A 26-week Single Site, Randomized, Double-blind, Active-controlled, Parallel Group, Human PoC Study to Evaluate Superiority of RK-01, Valsartan Plus Celecoxib Addon to Metformin Versus Metformin Alone in Type 2 Diabetes Patients
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Type 2 Diabetes
High Blood Pressure
Arthritis
Obesity
Keywords: Diabetes
Obesity
FPG
Beta cell function index
HbA1c
Atherogenic index
Lead sponsor: ARKAY Therapeutics
Sponsor class: INDUSTRY
Collaborators: name: Albany Medical College
name: Myopharm Limited
First posted: 2018-09-27
Enrollment: 115
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Evaluation of safety, tolerability and superiority of RK-01, a valsartan plus celecoxib dual add-on to metformin-HCL XR over metformin in newly diagnosed and obese adult type 2 diabetes patients with high blood pressure, arthritis and inadequate glycemic control with metformin monotherapy, diet and exercise over 26 weeks of treatment.

Objective: To assess effect of RK-01 on HbA1c levels, beta cell function and insulin resistance with co-administration of valsartan, celecoxib and metformin-HCl XR relative to metformin monotherapy.

Hypothesis: After 26 weeks of treatment with valsartan, celecoxib and metformin-HCl XR provides greater improvements in glycemic, inflammatory and atherogenic parameters compared to metformin monotherapy.

Detailed description: PRIMARY:

In patients with type 2 diabetes with inadequate glycemic control with metformin monotherapy:

Objective: To assess effect of RK-01 on HbA1c levels, beta cell function and insulin resistance with co-administration of valsartan, celecoxib and metformin-HCl XR relative to metformin monotherapy. Improvements in glycemic, inflammatory and atherogenic parameters including beta cell function relative to adult healthy volunteers with normal glucose tolerance (NGT) treated with placebo for 26 weeks will also be assessed. An interim study assessment will also be performed after 12 weeks of treatment.

Hypothesis: After 26 weeks of treatment with valsartan, celecoxib and metformin-HCl XR provides greater improvements in glycemic, inflammatory and atherogenic parameters compared to metformin monotherapy.

Eligibility criteria: Inclusion Criteria:

1. Males and females, Age: \>18 to 70 years at the time of screening visit.
2. Women of childbearing potential (WOCBP) must have negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent of HCG) within 24 hours prior to the start of the study.
3. Women must not be breastfeeding.
4. HbA1c≥8.0
5. Patients with inadequate blood glucose control with Metformin defined as a central laboratory glycosylated hemoglobin (HbA1c) \>8.0 and \<10.5 obtained at the screening visit. Metformin-HCl monotherapy was inadequate 3 months prior to the study as indicated by the lack of decrease and/or an increase in the A1c level.

   Newly diagnosed drug naïve patients as defined by HbA1c\>7.0 at the screening visit. Drug naïve subjects diagnosed with type 2 diabetes within 6 months of diagnosis will be considered and selected.

   About half the patients are expected to be newly diagnosed in the study.
6. Drug naive as well as osteoarthritis patients with Type 2 diabetes receiving a non-aspirin pain reliever (e.g. acetaminophen) or an NSAID (e.g. Naproxen).
7. Max/maintenance dose Metformin. Subjects should have been taking the same daily dose of metformin for at least 8 weeks prior to the enrollment visit and subjects not receive these other antihyperglycemic medications within the 12 weeks prior to screening (except for short-term use of insulin \[≤7 days\] during concomitant illness or other stress).
8. Patients with \>25% AIRg at 2 minutes and 10 minutes.
9. RAS blocker naïve patients
10. 2-Hour OGTT ≥200 mg/dL
11. FPG ≥140 mg/dL
12. BMI ≥30
13. Impaired first phase and second phase of insulin secretion
14. BP ≥140/90 mm Hg (These patients might be on an anti-hypertensive drug)
15. Non-fasting laboratory glucose \>200 mg/dL with symptoms of polydipsia, polyuria and/or Polyphagia
16. eGFR ≥ 60 ml/min/1.73m2

Exclusion Criteria:

1. Age \>70
2. Patients with Type 1 diabetes, Screen for GAD (Glutamic acid decarboxylase) antibodies at the time of screening visit. To rule out latent autoimmune diabetes in adults (LADA), screening for other diabetes-related antibodies, such as insulinoma-associated protein (IA-2 and IA-2 beta), zinc transporter-8 (ZnT8), islet cell antibodies (ICA) or insulin autoantibody (IAA) will also be considered.
3. Pregnant women
4. Patients with a history of Ketoacidosis.
5. Subjects at serious risk of gastrointestinal (GI) adverse events (e.g. current or recent history of GI bleeding ulceration, or perforation).
6. Subjects with a planned radiologic study with intravenous contrast, surgery, or other planned procedures that may predispose them to metformin-associated lactic acidosis.
7. Insulin dependent: \<25% Beta-cell function: AIRg (Acute insulin response to glucose after 2 min and 10 min after glucose injection) INSULIN DEPENDENT STATE.
8. Patients with a history of uncontrolled hyperglycemia \>15.0 mmol/L (280 mg/dL) after an overnight fast that required rescue therapy.
9. Patients with uncontrolled hyperglycemia \>15.0 mmol/L (280 mg/dL) after an overnight fast that required rescue therapy during week 1-3 Metformin-HCl monotherapy or RK-01 therapy.
10. eGFR, impaired kidney function \< 60 ml/min/1.73m2.
11. Poor metabolizers of Cyp450 2C9 to avoid very high concentration (Since Cytochrome 450 2C9 is responsible for the metabolism of both Valsartan and Celecoxib, patients who are known or suspected to be poor Cyp450 2C9 metabolizers based on previous history will be excluded from the study).
12. Any of the following cardiovascular (CV)/Vascular diseases within 3 months of the enrollment visit:

    1. Myocardial infarction (MI)
    2. Cardiac surgery or revascularization (coronary artery bypass surgery, Coronary Artery Bypass Graft \[(CABG\]/Percutaneous transluminal coronary angioplasty (PTCA)\].
    3. Unstable angina
    4. Unstable congestive heart failure (CHF)
    5. Transient ischemic attack (TIA) or significant cerebrovascular disease
    6. Unstable or previously diagnosed arrhythmia
    7. Congestive heart failure, defined as New York Heart Association (NYHA) Class III and IV, unstable or acute heart failure and/or known left ventricular ejection fraction of ≤40%.
    8. Acute coronary syndrome, stroke or transient ischemic attack within 3 months prior to the informed consent.
13. Previous bariatric surgery
14. Treatment with anti-obesity drugs within 3 months prior to consent
15. Patients with COPD
16. Patients with liver disease
17. Patients with renal disease
18. Patients with autoimmune diseases e.g. Lupus, Psoriasis
19. Patients with HIV/AIDS
20. Patients with diabetes-related complications
21. Patients with Hematological and Oncological Diseases/Conditions
22. Hemoglobin \<11.0 g/dL (110 g/L) for men; hemoglobin \<10.0 g/dL (100 g/L) for women
23. Patients with chronic disease e.g. Cancer, Epilepsy, Alzheimer, Parkinson, Asthma
24. Abnormal free T4
25. Patients with serious infection

Primary outcomes:
measure: Change in glycosylated Hemoglobin (HbA1c) for metformin background patients
timeFrame: Baseline and 26 weeks
measure: Change in glycosylated Hemoglobin (HbA1c) for treatment naive patients
timeFrame: Baseline and 26 weeks
measure: Change from baseline in acute insulin response to glucose (AIRg) for metformin background patients
timeFrame: Baseline and 26 weeks
measure: Change from baseline in acute insulin response to glucose (AIRg) for treatment naive patients
timeFrame: Baseline and 26 weeks
Secondary outcomes:
measure: Change in glycosylated Hemoglobin (HbA1c) to <7.0%
timeFrame: Baseline and 26 weeks
measure: Change from baseline in Body weight
timeFrame: Baseline and 26 weeks
measure: Change from baseline in fasting plasma glucose
timeFrame: Baseline and 26 weeks
measure: Change from baseline in Beta-cell function Index
timeFrame: Baseline and 26 weeks
measure: Change from baseline in insulin sensitivity index (ISI or Si)
timeFrame: Baseline and 26 weeks
measure: Change from baseline in glycosylated albumin (GA): glycosylated Hemoglobin A1c (HbA1c) ratio
timeFrame: Baseline and 26 weeks
measure: Change from baseline in HOMA2-b%
timeFrame: Baseline and 26 weeks
measure: Change from baseline in HOMA-IR
timeFrame: Baseline and 26 weeks
measure: Leptin/Adiponectin ratio
timeFrame: Baseline and 26 weeks
measure: Change from baseline in Atherogenic Index (AI)
timeFrame: Baseline and 26 weeks
measure: Change from baseline in glycosylated albumin (GA)
timeFrame: Baseline and 26 weeks
measure: Change from baseline in Leptin
timeFrame: Baseline and 26 weeks
measure: Change from baseline in Adiponectin
timeFrame: Baseline and 26 weeks
Other outcomes:
Locations:
city: Albany
country: United States
facility: Albany Medical College
state: New York
Study officials:
affiliation: ARKAY Therapeutics
name: Ravi Kumar, Ph.D.
role: STUDY_DIRECTOR
References: